Cancer chemotherapy update

Bevacizumab, etoposide, and cisplatin regimen for refractory brain metastases

Seth A. Mayer, Dominic A. Solimando, James Waddell

Research output: Contribution to journalArticle

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, email: waddfour@charter.net. Regimen Name: Bevacizumab, etoposide, and cisplatin (BEEP) Origin of Name: The regimen is named for the medications it contains: bevacizumab, etoposide, and cisplatin.

Original languageEnglish (US)
Pages (from-to)394-399
Number of pages6
JournalHospital Pharmacy
Volume52
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Oncology
Chemotherapy
Etoposide
Pharmacists
Refractory materials
Cisplatin
Names
Brain
Neoplasm Metastasis
Drug Therapy
Pharmaceutical Services
Poisons
Highway systems
Antineoplastic Agents
Neoplasms
Bevacizumab
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Cancer chemotherapy update : Bevacizumab, etoposide, and cisplatin regimen for refractory brain metastases. / Mayer, Seth A.; Solimando, Dominic A.; Waddell, James.

In: Hospital Pharmacy, Vol. 52, No. 6, 01.06.2017, p. 394-399.

Research output: Contribution to journalArticle

@article{04b3abc0a6be431fb350f78ae3a74a46,
title = "Cancer chemotherapy update: Bevacizumab, etoposide, and cisplatin regimen for refractory brain metastases",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, email: waddfour@charter.net. Regimen Name: Bevacizumab, etoposide, and cisplatin (BEEP) Origin of Name: The regimen is named for the medications it contains: bevacizumab, etoposide, and cisplatin.",
author = "Mayer, {Seth A.} and Solimando, {Dominic A.} and James Waddell",
year = "2017",
month = "6",
day = "1",
doi = "10.1177/0018578717717622",
language = "English (US)",
volume = "52",
pages = "394--399",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "6",

}

TY - JOUR

T1 - Cancer chemotherapy update

T2 - Bevacizumab, etoposide, and cisplatin regimen for refractory brain metastases

AU - Mayer, Seth A.

AU - Solimando, Dominic A.

AU - Waddell, James

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, email: waddfour@charter.net. Regimen Name: Bevacizumab, etoposide, and cisplatin (BEEP) Origin of Name: The regimen is named for the medications it contains: bevacizumab, etoposide, and cisplatin.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, email: waddfour@charter.net. Regimen Name: Bevacizumab, etoposide, and cisplatin (BEEP) Origin of Name: The regimen is named for the medications it contains: bevacizumab, etoposide, and cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=85032362836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032362836&partnerID=8YFLogxK

U2 - 10.1177/0018578717717622

DO - 10.1177/0018578717717622

M3 - Article

VL - 52

SP - 394

EP - 399

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 6

ER -